Part one of Covaxin's phase-1 vaccine trial is complete and the results are 'encouraging'

In steady progress in  human trials for India's COVID-19 vaccine COVAXIN, 50 participants across India have been administered so far, and results were 'encouraging'.

Dr Savita Verma, Principal Investigator of vaccine trial team at PGI Rohtak, Haryana said that part 1 of phase-1 human trial for Covaxin was completed as 50 patients were administered vaccine and results were encouraging. On Sunday, trials were conducted on six more people under part 2 of phase-1 human trials, results of which are awaited.

READ | COVID-19: AIIMS-Delhi Begins Recruiting Volunteers For Covaxin Human Trials

human trials for Covaxin commenced in Haryana on July 17 as Health Minister Anil Vij anunced that three participants were administered vaccine at  Post-Graduate Institute of Medical Sciences (PGI) Rohtak. ICMR has informed that approximately 1000 human volunteers are under clinical study in various test sites for two vaccine contenders - COVAXIN (ICMR-NIC with Bharat Biotech) and  ZyCov-D (Zydus Cadilla).

READ | 375 Healthy Volunteers; 150-day Monitoring: AIIMS Gets d For Covaxin Covid Vaccine Trial

Human trials of COVID vaccine begin in India

trials phase-1 & 2 have kicked-off combinedly in ICMR shortlisted locations - New Delhi, Patna, Chennai, Kanpur, Gorakhpur, Goa, Bhubaneswar, Rohtak, Hyderabad and Visakhapatnam among ors. Volunteers across country are undergoing assessment for all health parameters such as liver functions and infections and to check if y have COVID-19 infections as trials cant be done on COVID infected people or even asymptomatic patients. After assessment, subjects would be cleared for small doses of one of two vaccines and results will be studied.

READ | Bharat Biotech Begins First Phase Of Clinical Trials For India's Covid Vaccine 'Covaxin'

ICMR fast-tracks Covaxin trials

Earlier this month, ICMR fast-tracked Bharat Biotech India Ltd (BBIL)'s COVID-19 vaccine - Covaxin & Zydus Cadilla's ZyCov-D's clinical trials. Covaxin and  ZyCov-D were approved by DCGI recently to proceed to clinical trials after y showed promise in its pre-clinical data.

READ | ICMR Bolsters 'mid-August' Covid Vaccine Effort; Adds 12 Institutes For Covaxin Trial